Invasive Mold Infection: What It Is, Who’s at Risk, and How It’s Treated

Most of what we write about on this site is about long-term, debated illnesses linked to damp buildings. This post is about something different: infections where mold grows inside the body. They’re rare, but if you or someone you care for has a weakened immune system, it helps to know the warning signs and why they need fast medical care.

If you’re looking for the chronic, debated side of mold illness, see our pages on mold toxicity and CIRS instead.

The mainstream view first

The CDC describes invasive mold infections as “mold infections that affect blood vessels, deep tissues, or organs” ^[1]. The two most common are aspergillosis and mucormycosis ^[1]. Most infections start when someone breathes in mold spores, but mold can also enter through cuts or wounds or from contaminated medical equipment ^[1].

Mold spores are almost everywhere. “Most people, including people with weakened immune systems, inhale mold spores without any negative health effects,” the CDC says ^[1]. Aspergillosis and mucormycosis don’t spread from person to person ^{[5, 6]}.

The main types are:

• Invasive aspergillosis, caused by Aspergillus, a common mold. It’s the most severe form of aspergillosis and happens when the infection spreads from the lungs to other parts of the body ^[5].
• Mucormycosis, caused by a group of molds called mucormycetes. It can affect the sinuses, eyes and brain, the lungs, the skin, or the gut ^[7]. An international guideline says diagnosis “is often delayed, and disease tends to progress rapidly” ^[8].
• Rarer mold infections, such as those caused by Fusarium and Scedosporium. A 2021 global guideline says infections from molds other than Aspergillus and the mucormycetes “are increasing,” including “breakthrough” infections in people already taking antifungal medicine to prevent infection ^[9].

How it differs from mold allergy, ABPA and mold toxicity

The word “mold” covers several very different health problems. Knowing which one is being discussed helps you ask the right questions.

• Mold allergy is an allergic reaction. The American Academy of Allergy, Asthma & Immunology lists symptoms such as “sneezing, itchy, watery eyes, runny nose, nasal congestion” ^[3]. Mold isn’t growing inside the body.
• Allergic bronchopulmonary aspergillosis (ABPA) is an allergic form of aspergillosis that affects the lungs ^[10]. It most often occurs in people with asthma or cystic fibrosis ^[11]. An international guideline recommends screening newly diagnosed adults with asthma at specialist centers for sensitization to Aspergillus ^[12].
• Chronic pulmonary aspergillosis is a slow lung infection that develops over months. Experts say it is found in people who aren’t immunocompromised but have current or past lung disease, and diagnosis requires findings present “for at least 3 months” ^[13]. The CDC lists tuberculosis, COPD and sarcoidosis as risk factors ^[11].
• Mold toxicity and CIRS describe long-term illness that some clinicians link to living or working in water-damaged buildings. They’re debated in mainstream medicine. One 2019 review says “the existence of toxic mold syndrome has been disproven,” while agreeing that molds “can cause allergies and can be a trigger for asthma” ^[14]. Our mold toxicity and CIRS pages cover that debate.

Invasive mold infection is different from all of these: it’s a serious, life-threatening infection ^[1]. It’s diagnosed with tissue, fluid and imaging tests, and treated with prescription antifungal medicine ^[1].

Invasive mold infection vs. CIRS: why one is recognized and the other is debated

People who’ve read about mold illness often ask how invasive mold infection relates to chronic inflammatory response syndrome (CIRS). Both involve mold. They’re very different ideas, though, and mainstream medicine treats them very differently. The table compares them side by side. The mainstream view comes first, and the CIRS column describes how its practitioners frame it.

Why the CDC recognizes invasive mold infection

Invasive mold infection meets the usual standards for a recognized disease:

• The organism can be seen. Doctors can find the mold in tissue under a microscope or grow it in culture ^{[1, 10]}.
• There are objective tests. Imaging, biopsy and lab tests for parts of the fungal cell wall are used, and results are read alongside each patient’s situation ^{[1, 10]}.
• There are agreed case definitions. International experts (EORTC/MSGERC) sort cases into “proven,” “probable” and “possible” groups. A “proven” case can apply to any patient ^[23].
• There are treatment trials. In a randomized trial of 277 people with invasive aspergillosis, one antifungal led to more successful outcomes than an older one. Survival at 12 weeks was 70.8% vs. 57.9% ^[24]. Guidelines are built on trials like this ^[8].

Why CIRS isn’t recognized (yet)

CIRS doesn’t meet those standards so far:

• No consensus case definition. The criteria in use come from a committee of CIRS practitioners, not from a broad medical body ^[16].
• No validated diagnostic test. The German AWMF mold guideline says the visual contrast test and cytokine tests shouldn’t be used to diagnose mold-related illness “because there is insufficient scientific evidence” ^[20]. A NIOSH study of a water-damaged school found lower visual contrast scores in staff but said “we do not recommend using it in evaluation of people exposed to mold” ^[21].
• No large controlled trials. A 2024 review of CIRS treatment found 13 articles, including only two randomized trials ^[22]. The AWMF guideline lists the binder treatment used in CIRS protocols among “Treatment methods without sufficient scientific evidence” ^[20].
• Major bodies don’t endorse it. An American Academy of Allergy, Asthma & Immunology (AAAAI) position paper says many proposed mold-related illnesses “remain largely or completely unproved” ^[25]. The CDC’s main mold-and-health page covers allergy, asthma and lung infections, but it doesn’t mention CIRS ^[26].

Lack of recognition isn’t proof that an illness doesn’t exist. It means the evidence isn’t yet strong enough for consensus. CIRS researchers describe it as “under-recognized” and “underdiagnosed” ^[22], and some admit their own genetic research “is in its infancy” ^[18]. Larger, well-designed studies would help settle the question. Our CIRS testing and treatment post covers this debate in more detail.

Why it’s reasonable to ask whether mold contributes to CIRS-like illness

This is a hypothesis, not a proven fact. But it isn’t a far-fetched one:

• The same exposures already cause several recognized illnesses. Mold can cause allergy and trigger asthma ^[14], lead to ABPA in people with asthma or cystic fibrosis ^[11], and cause hypersensitivity pneumonitis, a lung inflammation from breathing in “dust, fungus, molds, or other substances” ^[27]. In people with weak immune systems, it can cause invasive infection ^[1].
• Major reviews link damp buildings to illness. The Institute of Medicine’s 2004 review found “sufficient evidence of an association” between damp indoor spaces and cough, wheeze, upper respiratory symptoms and asthma symptoms in sensitized people ^{[26, 28]}. The World Health Organization’s 2009 guidelines concluded that the main effects include respiratory symptoms, allergies and asthma “as well as perturbation of the immunological system” ^[29]. Damp homes are also linked to developing asthma ^[30], and repairing them reduced asthma-related symptoms in adults ^[31].
• Mold toxins affect the immune system in the lab. Some mycotoxins are described as “immunotoxic,” but “many of the studies are limited to animals or are relatively small human studies or case reports” ^[32]. Evidence: lab and animal studies; not proven in people with CIRS.
• Real-world studies hint at effects in water-damaged buildings. The NIOSH school study found more symptoms in staff at the damaged school ^[21]. Evidence: observational; it can’t show cause.

The key difference is mechanism. Invasive infection needs a weakened immune system and mold actually growing inside the body ^[1]. CIRS proposes something else: an inflammatory response to inhaled toxins or fungal fragments, mainly in people with certain gene types, without infection ^{[16, 18]}. Evidence for the CIRS model: practitioner consensus and small studies; not yet confirmed by independent large trials ^{[20, 22]}.

If you have ongoing symptoms you link to a damp building, work with a licensed clinician. Ask them to check for recognized problems such as asthma, allergy and hypersensitivity pneumonitis first, and to discuss your exposure history openly.

Who is at risk

“Most people are not at risk,” the CDC says ^[1]. Risk rises when the immune system is weakened by illness or treatment. The CDC lists:

• Transplants: organ, tissue or stem cell transplants ^[1]. Anti-rejection medicines work by weakening the immune system ^[33].
• Cancer and chemotherapy, especially blood cancers like leukemia and lymphoma ^[1]. Chemotherapy can lower white blood cell counts ^[33]. For invasive aspergillosis, the CDC lists severe or prolonged low counts of granulocytes, a type of white blood cell ^[10].
• Steroids and other immune-suppressing medicines, including high-dose corticosteroids and biologics ^{[1, 10]}.
• Diabetes, especially with a buildup of acid in the blood, for mucormycosis ^[6]. In a review of 851 published mucormycosis cases, diabetes was the most common underlying condition, found in 40% ^[34].
• Hospital and ICU care. Long hospital stays raise risk, and devices like ventilators and catheters can give fungi a way into the body ^[33].
• Severe COVID-19. COVID-19-associated pulmonary aspergillosis “usually occurs in patients with severe COVID-19 (e.g., patients on ventilators)” ^[35]. Experts say the virus damages the lining of the airways, “enabling aspergillus invasion” ^[36]. For COVID-associated mucormycosis, the CDC names uncontrolled diabetes and overuse of steroids as important risk factors ^[35].

Other listed risks for mucormycosis include neutropenia (low white blood cells), iron overload and long-term corticosteroid use ^[6]. Risk also rises when people with weakened immune systems are around a lot of mold, which is why the CDC calls invasive mold infections “a public health concern after hurricanes and floods” ^[1].

Symptoms

Symptoms depend on which part of the body is infected and on the person’s health beforehand ^[1]. In general, the CDC lists:

• Fever or night sweats ^[1]
• Cough, shortness of breath, and sinus symptoms ^[1]
• Chest pain and coughing up blood, especially with lung infections ^[19]
• Weight loss ^[1]
• Dark scabs, blisters or ulcers on the skin ^[1]

Mucormycosis of the sinuses, eyes and brain can cause one-sided facial swelling, headache, vision changes, congestion and black areas on the bridge of the nose or the upper inside of the mouth ^[7].

Because “most people who get invasive aspergillosis were already sick with other medical conditions” ^[19], new symptoms can be hard to tell apart from the illness someone already has. The CDC also notes that fungal diseases “are often misdiagnosed,” which can delay treatment ^[15]. If you’re in a higher-risk group and develop a new fever, cough, chest pain or any of these signs, contact your care team right away.

How it’s diagnosed

“Diagnosing an IMI requires multiple diagnostic tests,” and results have to be read in the context of each patient ^[1]. Tests your care team may use include:

• Imaging, such as a chest CT scan for lung symptoms ^[1], or CT or MRI to check whether infection is spreading ^[2].
• Samples from the affected area, such as fluid washed from the lungs during a bronchoscopy (bronchoalveolar lavage), nasal discharge or phlegm ^{[1, 2]}.
• Biopsy, culture and microscopy: a small piece of tissue is examined under the microscope (histopathology) and grown in the lab (culture) to identify the mold ^{[1, 10]}.
• Blood and fluid tests for fungal markers. A galactomannan antigen test detects part of the Aspergillus cell wall, and a beta-D-glucan test detects another cell-wall component ^[10]. Some labs also offer PCR tests for Aspergillus DNA ^[10]. These markers are typically negative in mucormycosis, so a negative result doesn’t rule it out ^[35].

Specialists classify cases as “proven,” “probable” or “possible” invasive fungal disease. A proven diagnosis can apply to anyone, while the probable and possible categories are meant for people with weakened immune systems ^[23]. Talking to an infectious disease specialist can help with diagnosis and treatment ^[1].

How it’s treated

Treatment needs to start quickly. “Mucormycosis is a serious infection and needs to be treated with prescription antifungal medication right away,” the CDC says ^[2], and an international guideline calls urgent surgical and medical treatment “lifesaving” ^[8].

• Antifungal medicines. There are only three main classes: azoles, echinocandins and polyenes ^[37]. Which one is used depends on the mold. Some antifungals that work for aspergillosis “do not work against the fungi that cause mucormycosis” ^[2], and drug resistance is emerging in Aspergillus fumigatus ^[5].
• Long courses. Antifungal therapy “may be required for weeks to months” ^[1]. It’s important to keep taking it for as long as prescribed, even if you feel better ^[37].
• Monitoring side effects. Antifungals tend to cause more side effects than other antimicrobials. More serious ones include liver problems with some azoles and kidney damage with amphotericin B ^[37]. Doctors sometimes measure drug levels in the blood to adjust treatment ^[37].
• Surgery to remove infected tissue, especially for mucormycosis ^{[2, 10]}.
• Reducing immune suppression where possible. The CDC says immune-suppressing medicines “should be discontinued or decreased, if possible” in invasive aspergillosis ^[10]. That’s a decision only your medical team can make.

Antibiotics don’t treat fungal infections and can even raise the risk of them ^[15].

Prevention

It isn’t possible to avoid mold spores completely ^[1]. For people at higher risk, the CDC suggests:

• Stay out of moldy buildings, and let someone else clean up. People with weakened immune systems “should not be involved in or present during mold removal from a home or building” ^[1]. After a flood, mold can grow if a home isn’t dried out within 24 to 48 hours ^[1]. Our guide to safe mold remediation covers cleanup.
• Avoid dust and soil. Avoid construction and excavation sites, and wear an N95 respirator if you can’t ^[11]. Avoid yardwork, gardening and areas affected by floods or leaks ^[6]. An N95 “does not offer complete protection” ^[1].
• Protect your skin. Clean skin injuries well with soap and water ^[11].
• Ask about preventive antifungal medicine and screening tests. Some high-risk patients, such as transplant recipients, are prescribed antifungals to prevent infection, and some may benefit from blood tests for early infection ^{[6, 11]}.
• Keep blood sugar under control, especially during illness. The CDC lists controlling blood sugar in people with diabetes who have COVID-19, and COVID-19 vaccination, as ways to lower the risk of COVID-associated mucormycosis ^[35].

The CDC is candid that although these steps are recommended, “they haven’t been proven to prevent aspergillosis,” and there are “no proven ways to prevent mucormycosis” ^{[6, 11]}. In hospitals, outbreaks have been linked to dust from renovation or construction ^[10].

The functional medicine view: supportive care alongside treatment

Many of our readers want to know how functional and integrative practitioners see a topic. Here, one point comes first: invasive mold infection is a medical emergency that needs prescription antifungal treatment. Nothing in this section replaces that. Anything here should only be used alongside treatment, with the approval of the medical team treating the infection.

Why functional medicine has little to say about invasive mold infection

Functional medicine was built for a different kind of problem. The Institute for Functional Medicine describes it as an approach that treats “the root causes of disease,” and says clinicians choose it for “improved outcomes with chronic disease patients” ^[38]. Invasive mold infection doesn’t fit that model:

• It’s acute and time-critical. It mainly strikes people whose immune systems are severely weakened by transplants, blood cancers, chemotherapy or strong immune-suppressing medicines ^[1], often around a hospital stay or intensive treatment ^[33]. “Starting treatment early can help prevent deaths,” and care is led by the treating team, often with an infectious disease specialist ^[1].
• There’s essentially no research. Our PubMed searches found no functional medicine studies and no clinical trials of integrative treatments for invasive mold infection ^[4].
• Functional mold work is about something else. Functional and environmental-medicine writing on mold focuses on chronic exposure illness such as CIRS and on mycotoxins, not on mold growing in tissue ^{[17, 32]}.
• Some approaches could get in the way. Herbal or “natural” antifungals and “detox” products haven’t been tested here, and some herbal products can interact with prescription antifungals ^[39]. Trying them first could also delay care, and delayed diagnosis and treatment of fungal disease can be deadly ^[15].

Where the two views do overlap is the supportive care listed below: a mold-safe environment, blood sugar control, nutrition, and close coordination with the treating team. Evidence: this section explains a gap in the research; it doesn’t mean functional approaches have been shown to help or harm in invasive infection.

How they frame it

We searched PubMed and found no published functional medicine research on invasive mold infections, and no clinical trials of integrative treatments for them ^[4]. Most functional and integrative writing on mold is about chronic exposure illness instead. The International Society for Environmentally Acquired Illness (ISEAI) uses “environmentally acquired illness” as an umbrella term covering several conditions, including CIRS, mast cell activation syndrome and multiple chemical sensitivity ^[17], and an article on its site compares a person’s “toxic load” to a bucket that can overflow ^[17]. The Institute for Functional Medicine teaches clinicians to assess “total toxic load” ^[40].

Evidence: these are organizing ideas for chronic illness, not tested approaches for invasive infection. A person with invasive mold infection needs a diagnosis and antifungal treatment from their medical team first.

Approaches that may come up, and where the evidence stands

• Removing mold exposure at home. Functional practitioners stress that it’s “equally as important to address the environmental factors” ^[17]. Here they agree with the CDC, which says people with weakened immune systems should avoid moldy buildings and stay away during cleanup ^[1]. Evidence: recommended by the CDC for people at risk, though not proven to prevent infection ^{[1, 11]}.
• Blood sugar control. The Institute for Functional Medicine teaches “nutritional support” as part of its approach ^[40]. For people with diabetes, attention to diet and blood sugar lines up with mainstream advice: the CDC lists blood sugar control as a way to lower the risk of COVID-associated mucormycosis ^[35]. Evidence: strong support for controlling blood sugar in diabetes, as part of medical care. Diet changes should be agreed with the treating team, especially during illness.
• Nutrition and food safety. People getting cancer treatment are sometimes told to follow a strict “neutropenic diet.” A 2015 meta-analysis of 4 studies with 918 patients found “no difference in major infection or mortality rates” compared with a regular diet ^[41]. A 2026 meta-analysis of 15 studies with 4,320 patients found the same overall, but said some high-risk patients, such as stem cell transplant recipients, “may still warrant cautious dietary practices” ^[42]. Evidence: moderate. It comes from cancer patients in general, not people with invasive mold infection. Follow your care team’s food-safety advice.
• Probiotics and gut support. Integrative mold treatments often include probiotics ^[32]. For people with very weak immune systems, a review of probiotic safety lists theoretical risks that include “systemic infections” and “excessive immune stimulation in susceptible individuals” ^[43]. Evidence: we found no randomized trials of probiotics in invasive aspergillosis or mucormycosis ^[4]. Don’t start them without asking your medical team.
• Herbal and “natural” antifungals and other supplements. Evidence: we found no clinical trials of these for invasive mold infection ^[4]. They can also interact with prescription antifungals. MedlinePlus warns that some herbal products, including St. John’s wort, may interact with one common azole antifungal, and advises keeping a list of every medicine, vitamin and supplement you take ^[39]. Tell your doctor and pharmacist about anything you take.
• Binders, sauna and other “detox” approaches. These come from the chronic mold illness world ^[32]. Evidence: none for invasive infection. A review that supports binders notes they can “bind medications, vitamins, and nutrients” and should be taken hours apart from medicines ^[32], which could matter for antifungals taken by mouth. The medical evidence for sauna’s claimed benefits “is not well established” ^[44]. Avoid these during treatment unless your medical team approves.
• Mind-body support. Integrative oncology studies complementary approaches for people with cancer, many of whom are also at risk for invasive mold infection ^[1]. A Society for Integrative Oncology and ASCO guideline recommends mindfulness-based programs, yoga, relaxation, music therapy and other approaches for anxiety during cancer treatment, while noting limits in the evidence ^[45]. Evidence: moderate. The guideline says approaches such as mindfulness and yoga “appear effective” for anxiety and depression symptoms in people with cancer, but notes limits in the research ^[45]. It doesn’t treat infection, but it may help with the stress of a long illness.

Working with a clinician. If you want an integrative approach, look for a licensed clinician who will work with your infectious disease or transplant team, not around them. Bring a list of everything you take to every appointment ^[39].

What’s known and what’s debated

Generally accepted: invasive mold infections are rare, serious and mainly affect people with weakened immune systems ^[1]. They need prompt diagnosis and prescription antifungal treatment, sometimes with surgery ^{[1, 8]}. Antifungals don’t work equally against every mold ^[2].

Still being studied: which transplant patients are at highest risk and how best to prevent fungal infections ^[11], how to handle drug resistance ^[5], and how best to manage rarer molds such as Fusarium and Scedosporium ^[9]. Integrative and functional approaches haven’t been studied for invasive mold infection ^[4].

Questions to ask your doctor

• Am I at higher risk for invasive mold infection, and which symptoms should make me call right away?
• Should I take medicine to prevent fungal infections, or have blood tests to check for early infection?
• If an infection is suspected, which tests will you use, and how soon will we know?
• Which antifungal are you recommending, how long will I take it, and what side effects should I watch for?
• Could any of my other medicines or supplements interact with it?
• Is it safe for me to be at home if there’s mold or water damage, and who should clean it up?
• Can an integrative or functional approach be added safely, and will you coordinate with that clinician?

Our symptom checklist and doctor visit prep sheet can help you organize what to bring.

The bottom line

Invasive mold infection is rare, but for people with weakened immune systems it’s an emergency that needs fast testing and prescription antifungal medicine ^{[1, 2]}. Supportive care, including some approaches integrative practitioners value, such as a mold-free home, blood sugar control and stress support, can sit alongside that treatment, but never replace it. For the chronic, debated side of mold illness, see our mold toxicity and CIRS pages, and you can read about our own experience in our story.

Sources

Numbers in brackets in the text link to these sources. Links were checked in October 2026. Some sources are written by people who support a particular approach; we've tried to say so in the text.

1. Centers for Disease Control and Prevention (CDC). About Invasive Mold Infections. Web page, accessed October 31, 2026. https://www.cdc.gov/fungal/about/about-invasive-mold-infections.html
2. CDC. Mucormycosis Testing and Treatment. Web page, accessed October 31, 2026. https://www.cdc.gov/mucormycosis/treatment/index.html
3. American Academy of Allergy, Asthma & Immunology (AAAAI). Mold Allergy (patient page; updated July 8, 2026). https://www.aaaai.org/conditions-treatments/allergies/mold-allergy
4. PubMed (U.S. National Library of Medicine). Searches: "functional medicine" AND (aspergillosis OR mucormycosis OR "invasive fungal") (0 results); "integrative medicine" AND (aspergillosis OR mucormycosis OR "invasive fungal") (8 results, none a clinical trial of a functional or integrative treatment for invasive mold infection); probiotic* AND ("invasive aspergillosis" OR mucormycosis), limited to randomized controlled trials (0 results). Searched October 31, 2026. https://pubmed.ncbi.nlm.nih.gov/?term=%22functional+medicine%22+AND+%28aspergillosis+OR+mucormycosis+OR+%22invasive+fungal%22%29
5. CDC. Aspergillosis Basics. Web page, accessed October 31, 2026. https://www.cdc.gov/aspergillosis/about/index.html
6. CDC. Risk Factors for Mucormycosis. Web page, accessed October 31, 2026. https://www.cdc.gov/mucormycosis/risk-factors/index.html
7. CDC. Symptoms of Mucormycosis. Web page, accessed October 31, 2026. https://www.cdc.gov/mucormycosis/signs-symptoms/index.html
8. Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405-e421. PMID: 31699664. https://pmc.ncbi.nlm.nih.gov/articles/PMC8559573/
9. Hoenigl M, Salmanton-García J, Walsh TJ, et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infect Dis. 2021;21(8):e246-e257. PMID: 33606997. https://pubmed.ncbi.nlm.nih.gov/33606997/
10. CDC. Clinical Overview of Aspergillosis (for health care providers). Web page, accessed October 31, 2026. https://www.cdc.gov/aspergillosis/hcp/clinical-overview/index.html
11. CDC. Preventing Aspergillosis. Web page, accessed October 31, 2026. https://www.cdc.gov/aspergillosis/prevention/index.html
12. Agarwal R, Sehgal IS, Muthu V, et al. Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses. Eur Respir J. 2024;63(4):2400061. PMID: 38423624. https://pmc.ncbi.nlm.nih.gov/articles/PMC10991853/
13. Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016;47(1):45-68. PMID: 26699723. https://doi.org/10.1183/13993003.00583-2015
14. Chang C, Gershwin ME. The Myth of Mycotoxins and Mold Injury. Clin Rev Allergy Immunol. 2019;57(3):449-455. PMID: 31608429. https://doi.org/10.1007/s12016-019-08767-4
15. CDC. About Fungal Diseases. Web page, accessed October 31, 2026. https://www.cdc.gov/fungal/about/index.html
16. Shoemaker R, Johnson K, Jim L, et al. Diagnostic Process for Chronic Inflammatory Response Syndrome (CIRS): A Consensus Statement. Report of the Consensus Committee of Surviving Mold. Internal Medicine Review. 2018;4(5). https://www.survivingmold.com/Publications/CIRS_diagnostic_protocol_final_5_1_2018.pdf
17. Carnahan J. Exposure Concerns in Your Home? How an Indoor Environmental Professional Can Help. International Society for Environmentally Acquired Illness (ISEAI). October 4, 2021; updated February 29, 2024. https://iseai.org/exposure-concerns-in-your-home-how-an-indoor-environmental-professional-can-help/
18. Surviving Mold. Bi-weekly member questions, week of February 5, 2024 (Dr. Ritchie Shoemaker). https://www.survivingmold.com/physicians/dashboard/faq/bi-weekly-member-questions/week-of-february-5-2024
19. CDC. Symptoms of Aspergillosis. Web page, accessed October 31, 2026. https://www.cdc.gov/aspergillosis/signs-symptoms/index.html
20. Hurraß J, Heinzow B, Walser-Reichenbach S, et al. AWMF mold guideline "Medical clinical diagnostics for indoor mold exposure" - Update 2023. Allergol Select. 2024;8:90-198. PMID: 38756207. https://pmc.ncbi.nlm.nih.gov/articles/PMC11097193/
21. Thomas G, Burton NC, Mueller C, Page E, Vesper S. Comparison of work-related symptoms and visual contrast sensitivity between employees at a severely water-damaged school and a school without significant water damage. Am J Ind Med. 2012;55(9):844-854. PMID: 22566108. https://pubmed.ncbi.nlm.nih.gov/22566108/
22. Dooley M, Vukelic A, Jim L. Chronic inflammatory response syndrome: a review of the evidence of clinical efficacy of treatment. Ann Med Surg (Lond). 2024;86(12):7248-7254. PMID: 39649915. https://pmc.ncbi.nlm.nih.gov/articles/PMC11623837/
23. Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367-1376. PMID: 31802125. https://pmc.ncbi.nlm.nih.gov/articles/PMC7486838/
24. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408-415. PMID: 12167683. https://pubmed.ncbi.nlm.nih.gov/12167683/
25. Bush RK, Portnoy JM, Saxon A, Terr AI, Wood RA. The medical effects of mold exposure (AAAAI position paper). J Allergy Clin Immunol. 2006;117(2):326-333. PMID: 16514772. https://doi.org/10.1016/j.jaci.2005.12.001
26. CDC. About Mold. Web page, accessed October 31, 2026. https://www.cdc.gov/mold-health/about/index.html
27. MedlinePlus (US National Library of Medicine). Hypersensitivity pneumonitis. Web page, accessed October 31, 2026. https://medlineplus.gov/ency/article/000109.htm
28. Institute of Medicine (US) Committee on Damp Indoor Spaces and Health. Damp Indoor Spaces and Health. National Academies Press; 2004. PMID: 25009878. https://www.ncbi.nlm.nih.gov/books/NBK215643/
29. World Health Organization (WHO) Regional Office for Europe. WHO Guidelines for Indoor Air Quality: Dampness and Mould. 2009. PMID: 23785740. https://www.ncbi.nlm.nih.gov/books/NBK143941/
30. Quansah R, Jaakkola MS, Hugg TT, Heikkinen SA, Jaakkola JJ. Residential dampness and molds and the risk of developing asthma: a systematic review and meta-analysis. PLoS One. 2012;7(11):e47526. PMID: 23144822. https://pmc.ncbi.nlm.nih.gov/articles/PMC3492391/
31. Sauni R, Verbeek JH, Uitti J, Jauhiainen M, Kreiss K, Sigsgaard T. Remediating buildings damaged by dampness and mould for preventing or reducing respiratory tract symptoms, infections and asthma. Cochrane Database Syst Rev. 2015;(2):CD007897. PMID: 25715323. https://pmc.ncbi.nlm.nih.gov/articles/PMC6769180/
32. Hope J. A review of the mechanism of injury and treatment approaches for illness resulting from exposure to water-damaged buildings, mold, and mycotoxins. ScientificWorldJournal. 2013;2013:767482. PMID: 23710148. https://pmc.ncbi.nlm.nih.gov/articles/PMC3654247/
33. CDC. Risk Factors for Fungal Diseases. Web page, accessed October 31, 2026. https://www.cdc.gov/fungal/risk-factors/index.html
34. Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26-34. PMID: 30036666. https://doi.org/10.1016/j.cmi.2018.07.011
35. CDC. Fungal Diseases and COVID-19 (for health care providers). Web page, accessed October 31, 2026. https://www.cdc.gov/fungal/hcp/covid-fungal/index.html
36. Koehler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021;21(6):e149-e162. PMID: 33333012. https://pmc.ncbi.nlm.nih.gov/articles/PMC7833078/
37. CDC. Antifungal Treatment (About Antifungals). Web page, accessed October 31, 2026. https://www.cdc.gov/fungal/treatment/index.html
38. The Institute for Functional Medicine (IFM). What Is Functional Medicine? Web page, accessed October 31, 2026. https://www.ifm.org/functional-medicine
39. MedlinePlus (U.S. National Library of Medicine). Voriconazole (drug information). Web page, accessed October 31, 2026. https://medlineplus.gov/druginfo/meds/a605022.html
40. The Institute for Functional Medicine. Environmental Health Advanced Practice Module (course overview). Accessed October 23, 2026. https://www.ifm.org/environmental-health
41. Sonbol MB, Firwana B, Diab M, et al. The effect of a neutropenic diet on infection and mortality rates in cancer patients: a meta-analysis. Nutr Cancer. 2015;67(8):1230-1238. PMID: 26400721. https://doi.org/10.1080/01635581.2015.1082109
42. Jamal F, Kouli A, Alsulaiman A, et al. Neutropenic diet versus liberalized diet in patients with cancer: a systematic review and meta-analysis. JCO Oncol Pract. 2026 (published online September 10, 2026). PMID: 42721418. https://doi.org/10.1200/OP-26-00405
43. Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. 2015;60(Suppl 2):S129-S134. PMID: 25922398. https://pmc.ncbi.nlm.nih.gov/articles/PMC4490230/
44. Hussain J, Cohen M. Clinical effects of regular dry sauna bathing: a systematic review. Evid Based Complement Alternat Med. 2018;2018:1857413. PMID: 29849692. https://pmc.ncbi.nlm.nih.gov/articles/PMC5941775/
45. Carlson LE, Ismaila N, Addington EL, et al. Integrative oncology care of symptoms of anxiety and depression in adults with cancer: Society for Integrative Oncology-ASCO guideline. J Clin Oncol. 2023;41(28):4562-4591. PMID: 37582238. https://doi.org/10.1200/JCO.23.00857
46. MedlinePlus. Asthma. Web page, accessed October 10, 2026. https://medlineplus.gov/ency/article/000141.htm
47. MedlinePlus (U.S. National Library of Medicine). Anaphylaxis. Web page, accessed October 10, 2026. https://medlineplus.gov/ency/article/000844.htm
48. National Institute of Mental Health (NIMH). Help for Mental Illnesses. Web page, accessed October 10, 2026. https://www.nimh.nih.gov/health/find-help